DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • Sweden
  • /
  • Healthcare
Author Program NEWCreate Narrative
MNTC logo

Mentice AB (publ) Stock Price

OM:MNTC Community·SEK 382.5m Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 8 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

MNTC Share Price Performance

SEK 13.60
0.80 (6.25%)
​
SEK 13.50
Fair Value
SEK 13.60
0.80 (6.25%)
Fairly Valued intrinsic discount
SEK 13.50
Fair Value
Price SEK 13.60
AnalystLowTarget SEK 13.50
AnalystHighTarget SEK 28.50
AnalystConsensusTarget SEK 21.00
Fri, 24 Jul 26
Fair ValueSEK 13.50
Share Pricen/a

MNTC Community Narratives

AN
AnalystLowTarget
AnalystLowTarget's
Fair Value
·
Fair Value SEK 13.5 Fairly Valued intrinsic discount

Portable Simulation Shift And Rising R&D Needs Will Pressure Long-Term Prospects

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
AnalystHighTarget
AnalystHighTarget's
Fair Value
·
Fair Value SEK 28.5 52.3% undervalued intrinsic discount

Simulation And SaaS Recurring Revenue Will Drive Stronger Future Earnings Potential

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value SEK 21 35.2% undervalued intrinsic discount

Hospital Training Demand Will Drive Long-Term Upside From Advanced Simulation Platforms

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
MNTC logo
Mentice
Fairly Valued intrinsic discount

Portable Simulation Shift And Rising R&D Needs Will Pressure Long-Term Prospects

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Updated 24 Jul
Read Narrative
MNTC logo
Mentice
35.2% undervalued intrinsic discount

Hospital Training Demand Will Drive Long-Term Upside From Advanced Simulation Platforms

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 10 Jul
Read Narrative
MNTC logo
Mentice
52.3% undervalued intrinsic discount

Simulation And SaaS Recurring Revenue Will Drive Stronger Future Earnings Potential

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Updated 26 Jun
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystLowTarget
MNTC logo

MNTC: Rich Valuation Will Confront Lower Future Earnings Multiple Risk

Fair Value: SEK 13.5 Fairly Valued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystConsensusTarget
MNTC logo

MNTC: Upcoming Medical Device Orders And Partnership Will Support Stronger Profitability

Fair Value: SEK 21 35.2% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystHighTarget
MNTC logo

MNTC: New Imaging Partnership Will Drive Future Demand For Aneurysm Planning Tools

Fair Value: SEK 28.5 52.3% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Flawless balance sheet and undervalued.

1 Risk
3 Rewards
View Full Analysis

Mentice AB (publ) Key Details

SEK 303.1m

Revenue

SEK 35.2m

Cost of Revenue

SEK 267.9m

Gross Profit

SEK 272.5m

Other Expenses

-SEK 4.6m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
Nov 10, 2026
-0.16
88.37%
-1.52%
0%
View Full Analysis

About MNTC

Founded
1998
Employees
109
CEO
Frans Venker
WebsiteView website
www.mentice.com

Mentice AB (publ), together with its subsidiaries, develops, sells, and markets solutions for training and decision support in the clinical area of interventional angiography in cardiology, neurology, vascular surgery, and radiology. It operates through the Mentice VIST, Physical Sim, and Ankyras segments. The company offers virtual simulation products, including VR simulator platforms; procedural learning models; peripheral vascular; patient simulator accessories and extensions for endovascular therapies; and Angiosuite integrations, such as the VIST virtual patient and Laerdal SimMan vascular medical simulator. It also provides flow model products, which include physiological flow systems, extensions and add-ons, silicone and 3D printed vessels, and flow system accessories; Ankyras, a clinical decision application; Mentice Live, a cloud-based learning center for medical technology industry and healthcare providers; Right Heart Cath app, a mobile solution for interactive real-time exploration into the right heart catheterization procedure; Vascular Twin, an anatomical replication for procedural and device adoption; research and development services; and professional support services for installation, training, and warranty services. It operates in Europe, the Middle East, Africa, the Asia Pacific, and the Americas. Mentice AB (publ) was founded in 1998 and is headquartered in Gothenburg, Sweden.

Recent MNTC News & Updates

Analysis Article • Jul 27

Earnings Update: Mentice AB (publ) (STO:MNTC) Just Reported Its Second-Quarter Results And Analysts Are Updating Their Forecasts

Mentice AB (publ) ( STO:MNTC ) investors will be delighted, with the company turning in some strong numbers with its...

Recent updates

No updates

Mentice AB (publ) Competitors

MCAP logo

MedCap

Symbol: OM:MCAP
Market cap: SEK 7.9b
XVIVO logo

Xvivo Perfusion

Symbol: OM:XVIVO
Market cap: SEK 7.9b
ARJO B logo

Arjo

Symbol: OM:ARJO B
Market cap: SEK 7.5b
RAY B logo

RaySearch Laboratories

Symbol: OM:RAY B
Market cap: SEK 5.9b
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide